2017 Annual Conference Speakers

BioOhio is proud to present an amazing line up of moderators and panelists for the 2017 Annual Conference and 30th Anniversary Celebration. Below you will find brief biographies and links to their respective organizations.

(in order of appearance, additional speakers to be announced)

8:30 – Welcome Remarks

Bill-Dunlevy-PIC-125

Bill Dunlevy, BioOhio Board Chair, Vice President, Sales & Marketing, EG Industries

Bill is the Vice President of Sales & Marketing for EG Industries in Columbus, Ohio. EG Industries’ medical business unit is EG-GILERO. Before joining EG Industries, Bill spent seven years with Battelle as its Vice President and General Manager for the Consumer, Industrial and Medical business unit. A native Ohioan, Bill has spent his entire career in healthcare, initially working as an ICU Registered Nurse for five years. After business school, he started a 25+ year career in medtech and biopharma with leadership roles in sales, marketing, strategy and general management with Roche Diagnostics, Smiths Medical, Philips/Respironics, Karmel Medical and Hill-Rom. He holds degrees from: Anderson University, AS Nursing; Monmouth University, BS Business Management; and Capital University, MBA.

8:45 - Ohio Bioscience Timeline: 1803 to today

Join us for an insightful discussion and look back at how Ohio’s bio industry, and BioOhio, have grown.

john-lewis-120

Moderator, John F. Lewis Jr., President & CEO, BioOhio

John F. Lewis, Jr., a 4th generation Ohioan, is the President and CEO of BioOhio, Ohio’s bioscience membership organization. A graduate of Miami University (Ohio) and Capital University Law School, he is a licensed attorney with experience in international business, venture capital investments and economic development. He was a founding partner of the First Fifty Fund and Ohio TechAngel Fund. John has more than 18 years international experience, lived in Jamaica, Korea and China, the latter two with Perkin Elmer, while traveling to more than 42 others.

Baunach-Dorothy-200

Dorothy Baunach, Water Innovation Cluster Director, Cleveland Water Alliance

Dorothy Baunach, 1st & 3rd President of BioOhio (then EBTC), is a community and business leader with broad experience in organization and community development; strategic leadership; entrepreneurship; technology commercialization; business and early-stage capital formation; building collaborative programs among government, academia and industry; industry cluster development; non-profit management, fundraising; talent development, and STEM education. Dorothy has a thirty-year storied track record of successfully creating, transforming and leading organizations that today are part of Greater Cleveland’s and the state of Ohio’s nationally-recognized technology and innovation ecosystem. She has coached many entrepreneurs through the start-up process, created organizations to support them through Ohio’s Thomas Edison Program, and helped shape Ohio’s $2.3 billion Third Frontier initiative from its inception in 2002 through the second successful ballot initiative in 2010. Dorothy fostered the growth of technology-based industry sectors including, biomedical, health care technology, advance materials, alternative energy, flexible electronics, and information and communication technologies.

Coburn-Chris-200-Updated

Chris Coburn, Chief Innovation Officer Partners Healthcare (Boston, MA)

Chris Coburn leads a team of more than 110 tasked with the worldwide commercial application of the unique capabilities and discoveries of Partners’ faculty and its 60,000 employees. His unit’s business development responsibilities include industry collaborations, investing, international consulting, company creation, licensing, innovation management and capacity building. Prior to joining Partners, Mr. Coburn was the founding director of Cleveland Clinic Innovations and served for 13 years as its executive leader. During his tenure, Cleveland Clinic spun off 57 companies that raised more than $700M in equity financing. Cleveland Clinic had no technology based spin-offs before Coburn’s arrival. He also implemented an innovation alliance network in which Cleveland Clinic directly supports technology commercialization for healthcare systems throughout the United States. He is also a former Vice President and General Manager of Battelle Memorial Institute and Director at the Ohio Department of Development (now DSA) when the Ohio Edison Centers, including BioOhio, were founded in 1987.

Board-PKleinhenz-2017

Peter Kleinhenz, Managing Director, CID Capital, Venture Partner, Fletcher Spaght Ventures (Upper Arlington, OH)

Peter Kleinhenz has been actively involved in technology-based businesses as an entrepreneur, consultant, and investor for virtually all his professional career and specifically in the life sciences sector for over 20 years. Prior to joining CID in 2001, he served as Vice President of Commercialization for Battelle Memorial Institute. He was CEO and owner of Progenics, a medical device development and manufacturer. At Neoprobe Corporation, he was part of the founding management team and served in a variety of senior executive positions including CFO, Vice President of Manufacturing, and Vice President of Strategic Planning and Business Development. Peter received an MBA from Case Western Reserve University, his undergraduate degree from Loyola University of Chicago, and is a Certified Public Accountant licensed in Ohio.

Shah-Baiju-200

Baiju Shah, President & CEO, BioMotiv (Cleveland, OH)

Baiju Shah has extensive experience in supporting the launch of early-stage biomedical companies. Prior to BioMotiv, Mr. Shah was President and CEO of BioEnterprise, a business formation, recruitment and acceleration initiative that directly assists client companies in securing resources and funding to support their growth, and also serves as a catalyst for major industry initiatives such as new capital sources, translational centers, and real estate projects. During Mr. Shah’s decade long tenure, the initiative assisted in the creation, recruitment, and acceleration of more than 110 bioscience companies in Cleveland that collectively attracted $1.3 Billion in new funding, primarily from venture capital and private equity sources. The initiative’s success has been recognized with several national awards and has helped establish the region as a recognized center of bioscience innovation. Shah has been named an Ernst & Young Entrepreneur of the Year and has been recognized as one of Cleveland’s most influential leaders. He received a J.D. from Harvard Law School and a B.A. from Yale University.

9:35 - Fireside Chat: STERIS, an Ohio Success Story, Lessons Learned

Originally founded as Innovative Medical Technologies in 1985 and renamed STERIS in 1987, the company’s history dates back to 1894 with the founding of American Sterilizer Company, a long-time, global leading innovator of sterilization products. Today, through a series of strategic acquisitions and continual innovation of new products, STERIS holds one of the broadest portfolios of products in the industry. A pillar of Ohio’s medical device community, STERIS stands at the forefront of efforts to prevent infection and contamination in healthcare, pharmaceutical and medical device environments.

Isabelle-Billet-250

Moderator, Isabelle Billet, Owner and Principal, IBHC Advisors

Isabelle is a leader in the medical technology sector of healthcare with strong achievement in global strategy development and operational execution management in Europe and United States. She spent over 30 years within the management board of large divisions of publicly traded medical technology companies, including Johnson & Johnson Advanced Sterilization Products and Ethicon divisions, C.R. Bard and Cardinal Health, working directly with their Presidents to drive growth through commercialization initiatives, portfolio management, acquisitions of technology platforms and organic new product launches – contributing to over $0.5B growth during her tenure in these companies. She is now the Owner and Principal of IBHC Advisors, LLC where she provides growth strategy and operational consulting services in the medical technology segment. Isabelle has a doctorate degree in pharmacy from Montpellier University, France and an MBA from EMLyon, France and Cranfield School of Management, England.

Rosebrough-Walt-200

Walt Rosebrough, President & CEO, STERIS (Cleveland, OH)

Walt Rosebrough has been president and CEO of STERIS, a leading provider of infection prevention and procedural products and services, since 2007. He has held leadership positions in most major business functions, including product and business development, manufacturing, finance, and marketing. He has led ventures ranging in scale from start-up operations to multi-billion dollar, multinational businesses with thousands of employees. Prior to STERIS, Mr. Rosebrough served as CEO of Support Systems International (SSI), a leading provider of equipment and services to relieve complications of immobility. He was named CEO after SSI merged with Hill-Rom, a global leader in patient support systems, therapeutic products, and workflow information technology. Mr. Rosebrough currently serves on the board of AdvaMed, Health Insights, the Rock and Roll Hall of Fame + Museum, and Coastal Hydraulics. He is a member of the CCI Healthcare Executive Forum, a healthcare roundtable, and Chief Executives Organization. Mr. Rosebrough holds a bachelor’s degree in Industrial Engineering from Kettering University and an MBA from Stanford University where he was a GM Fellow and Arjay Miller Scholar.

sanford-bill

Bill Sanford, Founding President and CEO, STERIS, currently Principal and Owner, Symark LLC (Naples, FL)

Bill Sanford is Founder and Chairman of Symark LLC, a technology commercialization and business development organization. He is a dedicated practitioner and outspoken advocate of entrepreneurship, innovation, and bioscience commercialization. Among his commercialization successes is STERIS Corporation, a global leader in infection and contamination prevention systems, products, services, and technologies. As Executive Founder and Chairman of the Board, President, and CEO, he led STERIS in only ten years from a start-up with five employees and a $3 million valuation to a NYSE-listed public company with 5,000 employees and a market value of over $2 billion. Mr. Sanford is Chairman of Greatbatch, Inc. and a board member of Cleveland Clinic, ElectroSonics Medical, CardinalCommerce, Primus Capital Partners, and MicroGroup. He is founding and past Chairman of BioEnterprise, Chairman Emeritus of NorTech (Northeast Ohio Regional Technology Coalition), former Vice Chairman of BioOhio, and a charter member of the State of Ohio Technology Action Board.

10:25 - Fireside Chat: HTP, Ohio’s Original Health IT Success Story and CoverMyMeds, Ohio’s First Tech Startup Unicorn

In 2008 McKesson Corp. subsidiary RelayHealth acquired Healthcare Transaction Processors (HTP Inc.). Located in Columbus, Ohio, HTP focused on revenue cycle management and was at the time one of the state’s original health IT companies. HTP provided innovative connectivity solutions that addressed the growing burden of uncompensated healthcare, estimated to be $31.2 billion in 2006. Designed to connect providers, health plans and financial institutions, HTP’s solutions promoted timely reimbursement for patient services, ranging from verification of insurance eligibility to maintaining payment plans that aid in the collection of self-pay balances.

In 2008 Matt Scantland and Sam Rajan founded CoverMyMeds with the mission to help patients get the medication they need to live healthy lives by solving the problem of prior authorization. It’s a problem that impacts more than 185 million prescriptions each year, leads to medication abandonment and contributes to $300 billion in avoidable health care costs. CoverMyMeds’ software suite automates the medication prior authorization process for EHRs, providers, pharmacies and health plans, and is a leading electronic PA solution in the market. This year CoverMyMeds became Ohio’s first “unicorn”- a term coined for tech startups valued at more than $1 Billion – and was acquired by McKesson in April 2017.

Board-SGaines-2015-b

Scott Gaines, SVP & General Manager, Provider Solutions, CoverMyMeds

Scott has extensive business development, consulting and implementation experience in health IT. He currently leads the electronic health record (EHR) and health systems business for CoverMyMeds, the nation’s largest electronic prior authorization platform. Prior to CoverMyMeds, Scott spent nearly 10 years with Hyland, the creator of OnBase, where he most recently led an expansion into international markets. In this role, Scott had the opportunity to advise world-renown healthcare organizations in Europe, the Middle East, Asia and Australia. Scott is an active member of the CHIME Foundation, HIMSS (national), and Central & Southern Ohio HIMSS (local chapter). Scott holds numerous industry credentials, including a Certified Professional in Health Information and Management Systems (CPHIMS) certification, and has a Bachelor of Science degree in Finance from Miami University.

Shealy-Ray-200

Ray Shealy, CEO, Advisor, and Investor with SafeWhite, TicketFire, Kare Intellex (Columbus, OH)

Ray Shealy is a successful operator, investor and board member involved with a number of healthcare and technology-based companies. As a serial entrepreneur and active angel investor, Ray is adept at helping companies grow exponentially by focusing on strategy, innovation and execution and was selected by American Venture Magazine as one of the top “40 Under Forty” executives in the US in 2007. Ray served as the GM at McKesson’s RelayHealth unit after they acquired HTP Inc., an Inc. 500 and Healthcare Informatics Top 100 IT company, in 2008 where Ray served as President and CEO. Ray currently serves on the boards of SafeWhite, TicketFire, e-Cycle, and Rev1 Ventures. Ray also has served on the charitable Boards for the Central Ohio Dyslexia Association and Columbus City Year. Ray is a CPA and graduate of Ohio State University’s Honors Accounting Program.

10:50 - Keynote Address

AC2014-Stephen-McHale

IntroductionStephen McHale, Emeritus CEO and Chairman, Explorys

Stephen is Co-Founder and serves as Chairman of the Board of Directors and Executive Officer of Explorys. Stephen has had a 25-year career in founding, investing in and building technology companies. He is recognized for his focus in data mining and business intelligence related ventures. Most recently he served as the Chairman of the Board of Directors and CEO of Everstream, the company he founded in 1999 which was sold to Concurrent [NASDAQ: CCUR] in 2005. In 1985, Stephen founded McHale and Associates, Inc., a USConnect regional office, where he served as Chairman of the Board of Directors and CEO. He was a founding investor and served on the Board of Directors and as CEO of USConnect, an international systems integrator. USConnect generated aggregate revenues of $150 million until its sale to IKON Office Systems [NYSE: IKN] in 1997. Stephen is also Managing Director of 23Bell LLC Investments and an active Advisory Board Member to Genesis Inventions.

Stephen serves on the Board of Directors for the Center for Families and Children, a non-profit organization that makes success possible for people in Northeast Ohio’s most challenged communities. Stephen serves on the investment screening committee for the North Coast Angel Fund. He is also an active member of the Entrepreneurs Organization and Kent State University’s Health Informatics Advisory Council.

Anil-Jain-200

Anil Jain, SVP & Chief Medical Officer at IBM Watson Health (formerly Explorys)

Focused on the intersection of informatics, engineering, technology, clinical research and innovation, Dr. Anil Jain is VP and a Chief Medical Officer at Watson Health. He previously was Co-Founder, Senior VP and Chief Medical Officer of Explorys, Inc. formed in 2009 based on innovations that he developed while at the Cleveland Clinic. In April 2015, Explorys was acquired by IBM as an integral component of the newly formed Watson Health business unit.

In addition to serving on state and national committees focused on driving quality & research through Health IT, Dr. Jain has authored more than 100 publications and abstracts and has delivered numerous talks on the benefits of sustainable Health IT innovation, clinical informatics as well as big data and cognitive analytics.

After receiving a degree in Biomedical Engineering and a degree in Medicine from Northwestern University in Chicago, Dr. Jain began his post-graduate training in Internal Medicine at the Cleveland Clinic in 1995. In addition to joining the Department of Internal Medicine in 1998; until July 2011, served as Senior Executive Director of IT where he led Health IT innovations, including the e-Research programs, quality informatics and created solutions to monitor the “meaningful use” of EMRs to support the EHR Incentive Program. He has previously served as a leader within Better Health Greater Cleveland and is a former co-Director of Informatics of Case Western School of Medicine’s CTSA. He continues to practice and teach medicine part-time at Cleveland Clinic.

He is an active member of the Health Information Management & Systems Society (HIMSS) and the American Medical Informatics Association (AMIA) and is a Fellow of the American College of Medicine (ACP). He is also a Diplomat of the American Board of Internal Medicine (ABIM).

1:15 - Why We Do What We Do – Patient Stories

Rolf Benirschke will lead a panel of patients to discuss the real world impact of the bioscience industry.

Benirschke-Rolf

Rolf Benirschke, Pro-Bowl Placekicker, San Diego Chargers / Co-Founder, Chargers Hall of Fame / Chief Patient Officer, Legacy Health Strategies (San Diego, CA)

As the third most accurate placekicker in NFL history at the time of his retirement, Rolf Benirschke had an illustrious 10-year career with the San Diego Chargers. In his second season with the Chargers, Rolf was stricken with a life-threatening disease that led him to create a nationwide patient advocacy and support program for those facing ostomy surgery and IBD. For 36 years, Rolf has been providing inspiration and encouragement to patients around the world who live with Crohn’s disease, ulcerative colitis, colorectal and bladder cancer or other circumstances that can lead to ostomy surgery. He is the national spokesman for The Crohn’s & Colitis Foundation of America (CCFA), and The Rolf Benirschke Award was created in 2015 to honor community members who have made a significant impact locally for philanthropy, giving back, and leaving a lasting legacy. He was also granted the CCFA national award, The Modell Award for Business Leadership for exemplary volunteer leadership. He has helped raise almost $1 million in an effort to help find the cure for Inflammatory Bowel Disease. Rolf’s visionary work as a patient advocate led him to co-found Legacy Health Strategies in 2009, an industry-leading strategic marketing firm that develops patient support, disease awareness, and treatment compliance initiatives for medical device and pharmaceutical companies.

Click here to learn more about Rolf’s inspiring story.

Burkhart-Ian-250

Ian Burkhart, Patient Speaker, Dublin Jerome High School Boys Lacrosse Coach, Accounting student at The Ohio State University.

Ian Burkhart was born in Columbus, Ohio in 1991, one of four children. Growing up always adventurous and thrill seeking, he was a Boy Scout and lacrosse goalie throughout his teenage years. Mr. Burkhart started college at Ohio University in 2009 majoring in Video Production.  Shortly after his freshman year of college while on summer vacation, an ill-fated dive into a wave rendered him a quadriplegic.

Nearly six years after being paralyzed from his chest down, Ian Burkhart has regained control of his right hand and fingers with the help of a computer chip implanted in his brain and other technology that bypass his spinal injury. For the past three years, he’s been using this groundbreaking technology developed at Battelle and The Ohio State University, called NeuroLife, to bypass his spinal injury. When he is hooked up to the computer, and the computer is connected to a special sleeve wrapped around his forearm, he can use his hands to pick up and put things down. The technology reanimates his arm and allows him to control it with his mind.

Ian is currently a coach for the Dublin Jerome High School Boys Lacrosse team and in the process of an Accounting degree from The Ohio State University.

Watch a video about Ian’s journey here, and check out these media stories from CBS, Daily Mail, and NYT.

Hiznay-Matt-250

Matt Hiznay, Patient Speaker and Ph.D. Candidate at Case Western Reserve University/Cleveland Clinic.

Matt Hiznay is a five-year survivor of metastatic lung cancer and a Ph.D. candidate studying molecular medicine. He grew up in the small town of Poland, Ohio. After graduating from Poland Seminary High School in 2006, he enrolled at John Carroll University in University Heights, Ohio. While at John Carroll, Matt majored in chemistry, minored in biology, and earned a concentration in biochemistry-molecular biology. Matt graduated magna cum laude in 2010 with a Bachelor of Science degree. After graduation, he enrolled at the University of Toledo College of Medicine to become a physician.

In August, 2011, a persistent dry cough sent him to his family doctor. What followed were a flurry of scans, biopsies, and appointments, after which he was diagnosed with metastatic lung cancer—despite never having smoked a day in his life! The same day that Matt learned he had lung cancer, the U.S. Food and Drug Administration approved a new drug, crizotinib (Xalkori®, Pfizer). In clinical trials, crizotinib targeted his specific form of lung cancer by inhibiting the mutated ALK protein that was causing the cancer. After a harrowing hospital stay that included Matt twice suffering cardiac arrest, crizotinib worked. By November, Matt’s cancer was in remission.

Although Matt’s cancer has recurred multiple times, a combination of traditional chemotherapy, radiation treatments, and enrollment in two clinical trials have kept his cancer controlled. Last August, Matt celebrated the fifth anniversary of his diagnosis—a feat only one-percent of stage IV lung cancer survivors witness. Matt will graduate from Case Western Reserve University with his Doctor of Philosophy degree in January, 2018.

Watch a video about Matt’s journey here, and check out these media stories from Cleveland ClinicCure, and ecancer.

Ally-Hiznay

Aleksandra Stojkoska Hiznay, Pharmacist, Cleveland Clinic Avon Hospital

Aleksandra Stojkoska Hiznay is from Middleburg Heights, Ohio. Ally received a BA degree in Biochemistry from John Carroll University and a Doctor of Pharmacy (PharmD) from The Ohio State University. She completed her residency at St. John Medical Center in Westlake, Ohio.

2:15 – Best Practices in Licensing, Building an Innovation/Licensing/Start-up Culture, and how best to engage Industry

Hear what it takes to kick-start a technology and build a business from a panel of technology commercialization experts and experienced bioscience business development professionals. The synergy between academic research programs and the business world is critical to guiding products to market and addressing essential patient needs.

baord-sharrington-2016

ModeratorStephanie Harrington, MS, CEO, Matrix Medical Devices

Matrix Medical Device founder and visionary, Stephanie Harrington has over 20 years of management experience in the medical device industry, including regulatory affairs, quality system compliance, clinical studies, product development, and commercialization. Guiding startups and established companies alike through new product development and regulatory affairs management is her current mission. Previously, Stephanie served as Chief Operating Officer of Frantz Medical Development, responsible for new product development, manufacturing, and corporate regulatory and quality affairs. Stephanie also served as Vice President and Chief Regulatory Officer at Imalux, establishing the company’s quality system, 510(k) clearances and clinical studies. Prior to Imalux, she was Director, Research and Development at STERIS, responsible for product development of medical device reprocessing systems. Stephanie earned a Masters in Chemical Engineering from Stanford University and holds a BS in Chemical Engineering from the University of Maryland.

Brad-Beasecker

Brad Beasecker, CFO, ProteoSense

Mr. Beasecker is a successful, seasoned entrepreneur with a 30+ year career. As founder and president of a private investment banking firm focused on emerging companies, he was instrumental in the development of angel financing networks, and sourcing and evaluation of potential venture investment opportunities for his and other firms. Brad has also served as chair of a regional venture conference and president of the Columbus Venture Network for three years. He has authored and reviewed countless business and financing plans and is a recognized expert in the legal and tax communities on the valuation of businesses. He holds a BS with Highest Distinction in Economics (Honors Program) from Purdue University, an M.A. in Economics from The University of Michigan, and is a Chartered Financial Analyst. Brad has started multiple companies and in-licensed many technologies from many universities.

Joe-Jankowski-200

Joseph Jankowski, Ph.D., Chief Innovation Officer, Case Western Reserve Univeristy

In January, 2013, Dr. Jankowski became CWRU’s first Chief Innovation Officer.  In this capacity, he serves as a leader of – and contributor to – innovation occurring within the University’s research and educational programs.  He provides leadership to several on-campus commercialization and translational programs, including the Case Coulter Translational Research Partnership, Philips Global Advanced Imaging Innovation Center, and the Case Intellectual Property Venture Clinic. He is or was a founding director at NEOhio for-profits that include Arteriocyte, Neuros Medical, and Thermalin, and a trustee of BioEnterprise Corporation and JumpStart, where he serves on the Executive and Investment Approval committees. Dr. Jankowski holds a Ph.D. in Chemistry from the State University of New York’s College of Environmental Sciences, an M.B.A. from the Weatherhead School of Management and a dual B.S. in Chemical and Environmental Engineering Technologies from the University of Dayton.

Mike Pistone-300

Mike Pistone, Director of Business Development & Marketing, Center for Technology Commercialization, Cincinnati Children’s Hospital

Mike Pistone is the director of business development and marketing for Cincinnati Children’s commercialization office where he focuses on advancing and accelerating discoveries to the market where they can positively impact patient lives and the healthcare system. This includes managing a robust portfolio of therapeutics, diagnostics, software, and medical devices and partnering with pharmaceutical, biotech, medtech, and venture funds. Prior to his time at Cincinnati Children’s, he held strategic marketing and competitive intelligence positions in a variety of industries including industry, new ventures, and academia.

Jen-Veasey-200

Jennifer Veasey, Manager, New Product Research, US Endoscopy (a subsidiary of STERIS Corporation)

Jennifer Veasey has been with US Endoscopy/STERIS since 2007, where she managed the Polypectomy Portfolio of products for 5 years.  She was responsible for many new product launches, including US Endoscopy’s most successful polypectomy product to date.  In 2012, she joined the Research and Development team to focus on New Product Development initiatives and is currently responsible for managing the assessment of all new concepts and early stages of research in US Endoscopy’s Stage Gate Process.  Jennifer received a BA in English and Economics from Denison University.

3:30 – Startup / Shark Tank Pitch Competition

Building on the day’s theme, having seen where the industry has come from and where it may be headed, we take time to hear firsthand from companies that are leading the way with innovative new ideas. Seven companies chosen from Ohio’s Entrepreneurial Signature Programs will have seven minutes to pitch their product or service, followed by seven minutes of questions from a panel of Ohio experts.

Peeyush Shrivastava-200

Peeyush Shrivastava, Founder and CEO, Genetesis

Peeyush Shrivastava is the Founder and CEO of Genetesis. Prior to Genetesis, Peeyush co-founded Proscia, a digital pathology informatics company that leveraged cloud computing and artificial intelligence to bring biopsy analysis to the digital age. Peeyush started Genetesis in 2013 while studying biomedical science at The Ohio State University, and has been named Student Entrepreneur of the Year by the Entrepreneur’s Organization, served as a University Innovation Fellow, and recognized as one of Inc. Magazine’s 50 Emerging Global Entrepreneurs to Watch.

Genetesis-2017

Genetesis is a clinical-stage medical device company developing CardioFlux, a biomagnetic imaging tool to streamline the chest pain care in the emergency room. Genetesis builds systems which utilize advanced software that images and analyzes cardiac magnetic fields to determine the presence and location of heart disease. The device works quickly, noninvasively and without any radiation, and can scale for use in many different disease applications. Genetesis biomagnetic technology is a true platform, with the capabilities of revolutionizing how we approach medical care.

Bob Shalwitz-200

Dr. Robert Shalwitz, Founder and CEO, Invirsa

Dr. Shalwitz is the Founder and CEO, and he is a veteran in the pharmaceutical industry for over 20 years. Most recently, he was a founder of Akebia Therapeutics (founded in 2007, went public in 2014) where he led the development through phase 2b of a novel, oral therapy for anemia, and the early development of compounds for diabetic macular edema and inflammatory bowel disease. Previously, Dr. Shalwitz was with Reliant Pharmaceuticals and Abbott Laboratories where he led the medical teams gaining approval and launching of Lovaza® (Omacor) in the US.

invirsa-logo

Invirsa is a therapeutic company that is developing a compound that combats viral conjunctivitis (viral pinkeye) by enhancing the body’s own ability to fight the disease. Invirsa’s lead compound, INV-102, is derived from a naturally occurring small molecule that modulates the activity of three parallel enzyme systems that are critical to innate immune response. In vitro tests have already shown that INV-102 significantly reduces plaque formation caused by adenovirus (the main virus associated with infectious conjunctivitis). Reduced plaque indicates that there is less cellular injury and death caused by the virus.

Bill-Flickinger-200

Bill Flickinger, CEO, Managing Partner, MedInvent

William J. Flickinger is the CEO and Managing Partner at MedInvent, LLC. William co-founded MedInvent, LLC in 2008 and is the inventor of the NasoNeb technology. William is a 28-veteran of the medical device industry with experience in large and small companies including Medtronic, Inc., Synectics Medical, and Stereotaxis. A native of Northeastern Ohio, William relocated MedInvent to Northeastern Ohio in 2014.

MedInvent-logo

MedInvent is the manufacturer of the NasoNeb family of products including the NasoNeb® Nasal Nebulizer and NasoNeb® Powered Nasal Irrigator. The NasoNeb Nasal Nebulizer is designed specifically to deliver drugs to the nasal and paranasal sinus cavities. Unlike irrigation devices that are designed to wash the nasal cavity and leave little to no fluid behind, the NasoNeb System is designed to deliver medication throughout the nasal and paranasal sinus cavities in such a way that the medication stays in your nose and does not simply run down the sink.

Joe-DSilva-200

Joe D’Silva, Founder and CEO, Patients’ & Consumers’ Pharma

Joe D’Silva is the founder of Patients’ & Consumers’ Pharma. Joe’s passion is to use technology to improve global health and well-being in a cost-effective manner. P&C Pharma achieves this goal by providing personalized pharmaceutical products for optimum medication therapy. The Company’s first product – QuartetRx™ – serves the needs of patients who cannot swallow tablets and capsules. It is an easy-to-use automated device that compounds tablets and capsules into high-quality personalized flavored liquids. Joe is trained in the art and science of pharmacy, pharmaceutical engineering and physical chemistry and finds himself most fortunate to have found the Dayton area in which to relocate P&C Pharma.

P&CPharma-250

Patients’ & Consumers’ Pharma is a life-science company. We develop novel technologies that provide personalized pharmaceutical products for human and veterinary patients. We investigate the needs of patients with great care and employ innovative formulation approaches and patented mass-customization technologies. P&C Pharma provides unique cost-effective solutions to improve the dosing of medications, increase compliance and enhance therapeutic outcomes by the use of personalized pharmaceutical products.

Joseph Kittle

Joseph D. Kittle Jr., Ph.D, CEO, ProclaRx

Joseph D. Kittle Jr., Ph.D. has over 20 years of experience in the world of biotechnology. Dr. Kittle has expertise in the development of products and services in the areas of: Genome Engineering; Gene Synthesis; Realtime DNA Analysis; Genomics; as well as Protein Expression and Purification. He has held key positions at CODA Genomics (VP of Research and Technology), and at Lark Technologies (Director of New Products), where he displayed a keen understanding of product development along with a deep knowledge knowledge of chemistry, biochemistry, and synthetic biology. Dr. Kittle received his undergraduate degree in chemistry from Ohio University, then went on to Harvard, where he earned his Ph.D. in Chemistry. After completing his post doc work at Ohio State University in biochemistry in 1991, he worked as a scientist at Battelle for 3 years.

proclarx-200

ProclaRx, based in Athens OH, is a pre-clinical stage biopharmaceutical company with the exclusive worldwide rights to develop and commercialize our first-in-class anti-bacterial biofilm IP technology. ProclaRx is developing anti-infectives both as combination devices and as biologics. Our labs and regulatory and clinical partners optimize our commercialization pathways while keeping costs low.

Joseph-Gough-200

Joseph Gough, CEO and Founder, Wellopp

Joe Gough is the founder and CEO of Wellopp. Gough is in charge of all business strategy and product development decisions. He is a serial entrepreneurial having exited from other early stage companies such as CCS Robotics (sold to Swisslog in 2011). Gough was Entrepreneur in Residence at the University of Toledo Innovation Enterprises and an IT portfolio manager inside Rocket Ventures. Gough was Xology magazines Start-Up Entrepreneur of the Year and has won a variety of past awards in digital media and big data experience while consulting for LexisNexis and Reed Elsevier.

Wellopp-200

Wellopp is a digital health company committed to providing health plans and health systems with better outcomes and lower costs. Wellopp drives social determinants of health to the forefront of patient engagement with interactive survey tools, gamified digital outreach, and powerful motivational interviewing. The resulting real-time analysis and interventional programs help to create transformational experiences for chronically ill and socioeconomically vulnerable patients/members.

Sumithra-Jagannath-200

Sumithra Jagannath, President, ZED Digital

Sumithra Jagannath is a driven, technology-focused President with deep roots in software development. She is the Owner of ZED Digital, with Offices in Cleveland and Columbus. ZED specializes in Digital Personalization Trends in Software Development. Ms. Jagannath is a McGill University post graduate and served as professor of software usability at Concordia University graduate school in Montreal, Canada. She founded a consulting firm in software usability fresh out of college and has not looked back since. She now sits on the Web Development Board of Advisors at Franklin University and is the Ohio Chapter Director-at-Large in Marketing for Healthcare Businesswomen’s Association. Her expertise stems from her passion for computers and 20+ years of experience in software development and implementing usability engineering processes in organizations such as utility companies, banks and Government organizations. Through her career, Ms. Jagannath has led international teams based in Canada, India, USA and South Africa.

ZED-Digital

ZED Digital is a digital marketing and web development company. ZED Digital provides a software platform that powers personalized digital experiences for software, patient portals or websites. It aggregates data in real-time from multiple sources such as Electronic Health records, patient data, billing, hospital data and delivers it in a highly personalized manner based on the needs and preferences of each individual user. The technology can reduce patient readmissions and enhance the patient experience by over 80%.

Event-Bio-Theresa-Miles-150

Moderator, Theresa Miles, Director of Client Solutions, R&Q

Theresa has 18+ years’ experience highlighting an eclectic background as a leader in quality system compliance, clinical laboratory compliance, and clinical research activities. She has extensive skills and experience with CAPA development / execution, quality management systems, auditing and training. Theresa earned a Bachelor of Science degree in Biology from Saint Francis University. As Client Solutions Director, Theresa’s role for R&Q today includes working with new clients to solve their regulatory and quality challenges through offering balanced business solutions.

Sevy-Kraner

Judge, Sevy Kraner, Director, Biohealth, JobsOhio

Sevy Kraner is the Director for the Biohealth sector at JobsOhio. Prior to joining JobsOhio in early 2015, Sevy worked at Cardinal Health in the Nuclear Pharmacy Business. At Cardinal she focused on business strategy and worked with manufacturers to commercialize new radiopharmaceuticals. Before moving to Ohio, she worked in New York at Forest Laboratories and Jefferies Group where her experience ranged from implementing pricing and contracting strategies for branded pharmaceuticals to analyzing M&A, IPO and debt financing deals across the healthcare sector. Sevy currently resides in Columbus, Ohio with her husband and three daughters. She attended Vanderbilt University, where she earned a BA in Economics and Neuroscience.

Peter-ONeil-200

Judge, Peter O’Neill, Executive Director, Cleveland Clinic Innovations

Pete O’Neill is the Executive Director of Cleveland Clinic Innovations. Pete has 10+ years of experience at CCI. Prior to joining CCI, Pete held positions as Deputy Director of the Great Lakes Industrial Technology Commercialization Center, and product engineer at PCC Airfoils. He received his BS in aeronautical engineering from MIT.

AC2014-Sunnie-Southern

Judge, Sunnie Southern, Founder and CEO, Viable Synergy

Sunnie Southern is the Founder & CEO of Viable Synergy, a health technology and innovation firm, and the creator of the Community Innovation Program, Innov8 for Health. Sunnie is passionate about connecting innovative solutions with people who need them most. Her career includes launching over 30 products in a wide variety of health conditions, industries, and health care environments. This work has afforded her the opportunity to help 100s of health innovators around the world bring their ideas to life to support health care providers and help patients achieve their health goals.

Events